Skip to Content
Merck
All Photos(1)

Key Documents

4202101

Sigma-Aldrich

PRONOVA® SLG 100

sodium alginate solution, Mw 150-250 kDa, guluronate monomer units ≥60 %

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12162002
NACRES:
NA.25
Pricing and availability is not currently available.

Quality Level

100

sterility

sterile (Total viable count (CFU/g))

form

powder

mol wt

Mw 150-250 kDa

composition

guluronate monomer units, ≥60%
G/M ratio, ≥1

impurities

≤100 EU/g Endotoxins

pH

5.5-8.5 (20 °C, 1% in water)

viscosity

100-300 mPa.s, 1 % in water(20 °C)

Application

Examples of Pronova Alginates applications include: encapsulation of living cells and therapeutic proteins for cell therapy medications, cryoprotectant, bone putty binder for tissue engineering, 3D bioprinting, foams and cell tissue scaffolds, hydrogels, advanced drug delivery and implants, wound management, and medical devices.
SLG-100 is made from an alginate where over 60% of the monomer units are guluronate and is a highly purified and well-characterized sodium alginate. The molecular weight for PRONOVA SLG-100 is in the 200000 – 300000 g/mol range. The ultra low levels of endotoxins, proteins and product sterility allows for a big variety of in vitro and in vivo applications.

Legal Information

Product of Dupont Nutrition USA, Inc.
PRONOVA is a registered trademark of International N&H USA, Inc.

Disclaimer

NOT FOR USE IN HUMANS

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Rational Design of ECMs Toward Cancer Immunotherapy

Engineered ECMs enhance immune therapy in cancer treatment by supporting cells and tissues and modulating immune response. They improve immune cell maturation, expansion, and regulation through biomaterial manipulation, acting as frameworks or carriers for enhanced tumor immunotherapy.

Rational Design of ECMs Toward Cancer Immunotherapy

Engineered ECMs enhance immune therapy in cancer treatment by supporting cells and tissues and modulating immune response. They improve immune cell maturation, expansion, and regulation through biomaterial manipulation, acting as frameworks or carriers for enhanced tumor immunotherapy.

Rational Design of ECMs Toward Cancer Immunotherapy

Engineered ECMs enhance immune therapy in cancer treatment by supporting cells and tissues and modulating immune response. They improve immune cell maturation, expansion, and regulation through biomaterial manipulation, acting as frameworks or carriers for enhanced tumor immunotherapy.

Rational Design of ECMs Toward Cancer Immunotherapy

Engineered ECMs enhance immune therapy in cancer treatment by supporting cells and tissues and modulating immune response. They improve immune cell maturation, expansion, and regulation through biomaterial manipulation, acting as frameworks or carriers for enhanced tumor immunotherapy.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service